气球可扩展与自扩展在先前进行过外科手术的中枢替换的患者中,接受过导管大动脉替换的患者中
Lluis Asmarats1, Pilar Jiménez-Quevedo2, Ignacio J Amat-Santos3
1Hospital Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.
The Canadian journal of cardiology
|May 9, 2025
概括
过导管大动脉置换 (TAVR) 是安全有效的,在患者之前的额头气假肢. 气球扩展 (BEVs) 与自扩展 (SEVs) 相比,由于并发症较少,显示出更高的设备成功率.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 心脏外科手术 心脏外科手术
背景情况:
- 通过导管的大动脉置换 (TAVR) 在患有预先存在的 mitra 假肢的患者中提出了独特的技术挑战.
- 关于在这个特定患者群体中对TAVR的比较结果的数据有限.
研究的目的:
- 为了比较使用气球可扩展 (BEV) 和自扩展 (SEV) 系统的TAVR的结果,在之前手术中使用过米特拉假肢的患者中.
主要方法:
- 来自西班牙TAVR注册表的患者的分析,这些患者先前使用过外科手术的额头假肢.
- 主要终点包括门学术研究联盟-3的技术和设备成功,按门类型分层.
- 二次评估包括跨导管心脏 (THV) 栓塞,心交阻塞,THV性能和心脏起器植入率.
主要成果:
- 在243名患者 (37%BEV, 63%SEV) 中,整体技术成功率高 (95.9%).
- 三十天的设备成功率显著高于BEVs (94.4%vs85.0%,P=0.036),归因于较低的中度残留大动脉吐和THV栓塞率.
- 接受BEV患者的平均跨膜梯度较高,永久心脏起器植入率较低.
结论:
- TAVR是一种安全有效的手术,适用于患有先前存在的 mitra 假肢的患者,不论THV类型.
- 气球膨胀 (BEVs) 提供了卓越的设备成功,主要是由于减少THV栓塞和残留大动脉吐,与自我膨胀 (SEVs) 相比.
相关概念视频
Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...


